Business Context and Reporting Period
MedTech Acquisition Corporation (MTAC) filed this Form 8-K on December 21, 2022. The filing primarily provides Regulation FD disclosure regarding its proposed business combination with TriSalus Life Sciences, Inc. Under the November 11, 2022 merger agreement, MTAC’s wholly owned subsidiary would merge with TriSalus, with TriSalus surviving as a wholly owned subsidiary. Upon closing, MTAC is expected to be renamed TriSalus Life Sciences, Inc.
Key Financial Metrics
This Form 8-K does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It is not a financial results filing.
Material Changes and Transaction Status
- MTAC and TriSalus released a video statement and social media updates concerning the ongoing Pressure-Enabled Regional Immuno-Oncology 01 and 02 clinical studies for primary and metastatic liver tumors.
- MTAC intends to file a Form S-4 registration statement containing a proxy statement/prospectus. The registration statement was not yet effective as of the filing date.
- Completion of the business combination remains subject to conditions including MTAC stockholder approval, satisfaction of a minimum cash condition after any public-stockholder redemptions, applicable governmental and regulatory approvals, and other conditions in the merger agreement.
Outlook, Commentary, Risks, and Unusual Items
The filing discusses forward-looking expectations regarding the tolerability of SD-101 delivered through TriSalus’s TriNav Infusion System, the potential of its Pressure-Enabled Drug Delivery method, clinical-program development, topline data, regulatory approval, competition, and commercialization.
Material risks include failure or delay of the business combination, inability to obtain an extension of MTAC’s transaction deadline, insufficient cash following redemptions, failure of clinical trials or regulatory approval, reimbursement changes, inability to fund trials or raise additional capital, competition, difficulty growing TriNav sales, Nasdaq listing risks, legal proceedings, transaction costs, and failure to realize projected benefits or pro forma results.
The clinical-study updates and related exhibits were furnished under Item 7.01 and were not deemed filed for purposes of Section 18 of the Exchange Act. The filing also states that external data and projections were not independently verified and may be preliminary or subject to change.
Facts Investors Should Verify
- Whether the Form S-4 registration statement was subsequently filed and declared effective, and review its proxy statement/prospectus.
- MTAC stockholder approval status, the applicable transaction deadline, and whether any deadline extension was obtained.
- Expected public-stockholder redemptions and compliance with the minimum cash closing condition.
- Clinical-trial enrollment, safety, efficacy, topline results, and regulatory status for the Pressure-Enabled Regional Immuno-Oncology studies.
- TriSalus’s audited financial statements, cash position, debt, operating losses, cash-burn rate, financing needs, and reimbursement environment in subsequent filings.
- Final merger consideration, ownership percentages, dilution, transaction costs, and any changes to the merger agreement.